Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713437 · ClinicalTrials.gov registry record
Measurement of Beta Cell Death in Individuals With Cystic Fibrosis
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 40
- Enrollment target
NCT03713437: Completed study, sponsored by University of Nebraska.
NCT03713437 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03713437 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.
Primary Outcome
Levels of differentially methylated insulin DNA in people with CF from infancy to young adulthood will be measured and compared to levels in healthy, age-matched controls.
Interventions
- DIAGNOSTIC_TEST Measurement of differentially methylated insulin DNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2021-06-30 |
What the finished NCT03713437 record still lists
NCT03713437 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Measurement of differentially methylated insulin DNA is the first listed.
NCT03713437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03713437 about?
NCT03713437 is a clinical study titled "Measurement of Beta Cell Death in Individuals With Cystic Fibrosis". This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants ...
What is the current status of trial NCT03713437?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2019-04-04. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03713437?
The interventions under investigation include: Measurement of differentially methylated insulin DNA (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03713437?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI